

Aiming to be self-supporting in the future,
the foundations were laid firmly in FY2013

RESEARCH

Exploring the seeds thoroughly in hospital visits

In search of promising seeds in the network, we are visiting our group hospitals in turn from FY2013, centering on Okayama University Hospital's "The Center for Innovative Clinical Medicine."

SYSTEM

Building a foundation of information sharing throughout the network

In anticipation of mid- to long-term development and expansion, including the introduction of a cloud-based patients' recruiting system and intensive use of the disease-specific data management system already operating, development of database management compatible with clinical trials in compliance with ICH-GCP, has begun.

Supporting the multi-center clinical research

Creating unified standard operating procedures and assuring ethics, scientific nature and reliability, in order to support joint clinical research at multiple hospitals led by the Okayama Univ. Hospital.

MANAGEMENT

Mid-West Japan Clinical Study Consortium Liaison Conference

27 September 2013

About 50 participants from consortium hospitals and practitioners attended. There were lively questions about promoting clinical research being conducted by each university hospital



Clinical Study Core Hospital Kick-off Symposium

5 October 2013

There were 170 participants, including researchers and pharmaceutical companies. There was a panel discussion on the current state and direction of clinical research promotion as a university hospital.



The First National University Hospital Clinical Research Promotion Liaison Conference at the district of Chugoku and Shikoku regions

28 November 2013

A liaison conference for the Chugoku and Shikoku regions was held. The status of efforts to expand clinical research promotion and issues for each ten universities were shared, and views were exchanged.



One year will soon have passed since Okayama University Hospital was designated as a clinical study core hospital. Presently, by positioning the health and medical field as a growth strategy industry and activating the medical industry, the government is working not only to contribute to the growth of the Japanese economy, but also to provide the world's most advanced medical technology and services to the people. Clinical study core hospitals play an important role as a key hospital in the development of drugs and medical devices for all Japan toward the realization of those goals.

The Okayama University Hospital belongs to the Mid-West Japan Clinical Study Consortium established in November 2012, which functions as a "Mega-Hospital", and while collaborating with the Chugoku and Shikoku region's national university hospitals, we will make further efforts to realize the objectives raised by the government, to develop medical care and share those results with society.


Hirofumi Makino, Director of Okayama University Hospital

Okayama University Hospital
Center for Innovative Clinical Medicine
2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
tel: 81-86-235-6503 fax: 81-86-235-6505
email: ouh-csnw@adm.okayama-u.ac.jp

Okayama University Hospital Clinical Study Core Hospital
<http://www.hsc.okayama-u.ac.jp/hos/core/>



Okayama University Hospital Clinical Study Core Hospital Result Report (2014 version) Summary version



Promoting clinical research aimed at results from the patient's perspective

commercialization and



Clinical studies of anti-HCV and antimalarial drugs, as compounds of invention

First In Man study implementation of antimalarial and anti-hepatitis C virus drugs and research on improved formulations for phase III study

Anti-HCV drugs

- Feature (1) Very inexpensive compared to other drugs Contributing to hepatitis C treatment in Asian countries
- Feature (2) For refractory cases in which interferon is ineffective or can't be used

Antimalarial drugs

- Feature (1) Broad scope including injection and dermal absorption as well as oral
- Feature (2) Salvage treatment after the current development of drug resistance to antimalarial drugs

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences



Yusuke Wataya, Special Professor

Nobuyuki Kato, Professor




Kim Hye-sook, Associate Professor

Hiroyuki Doi, Professor

Realization of the optimal dose expansion long desired in the field of breast cancer treatment through academia in Japan

Pharmacokinetic study of docetaxel 100 mg/m² for advanced or metastatic breast cancer

- Feature (1) The international standard for breast cancer treatment
- Feature (2) The world standard therapeutic dose available in Japan
- Feature (3) Increased Japanese participation in international collaborative clinical studies of this drug




Taizo Hirata, Associate Professor, Okayama University Hospital, Center for Innovative Clinical Medicine

Hope for blind patients Recovery of vision by artificial retinas

Investigator-led clinical trials of Okayama University-oriented retinal prosthesis

- Feature (1) Much less expensive than existing products (¥10 million → ¥400 thousand)
- Feature (2) Current standard surgical techniques can be used
- Feature (3) Stimulates nerve cells without using electrodes




Tetsuya Uchida, Associate Professor, Okayama University Graduate School of Natural Science and Technology (Engineering)

Toshihiko Matsuo, Associate Professor, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences (Medicine)

Promising option of standard treatment for refractory chronic GVHD

Multicenter investigator-led clinical study of tamarotene that targets refractory chronic graft-versus-host disease

- Feature (1) Bench to bedside physician-led phase II study for refractory chronic graft-versus-host disease (GVHD)
- Feature (2) Tamarotene may become a promising option of standard treatment for refractory chronic GVHD, for which a standard treatment has not been established
- Feature (3) A multi-center clinical trial all over Japan



Yoshinobu Maeda, Assistant Professor, Okayama University Hospital Department of Hematology and Oncology

Introducing articaine, "the world standard" dental local anesthetic, into Japan

Investigator-led study of the dental local anesthetic articaine

- Feature (1) Introduction of articaine is the world's standard drug
- Feature (2) Strong analgesic effect for painless dental treatment
- Feature (3) Quickly metabolized and highly safety drug for a super-aging



Takuya Miyawaki, Professor, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences (Okayama University Hospital Dental Anesthesiology)

Okayama University Hospital has a variety of seeds besides the support seeds

- **(World first)** Realizing the transplant of the middle lobe of living lung from mother to child of small physique. The dawning of organ transplant in children
- **(World first)** Producing cancer stem cells from iPS cells, with the aim of clarifying the actual conditions of cancer by studying the processes of cancer tissue
- **(World first)** Clinical research on treatment with the tumor suppressor gene (REIC), attacking only cancer with almost no side effects
- **(World first)** Clinical study of regenerative medicine for functional single ventricle in children, improving the heart's pumping capacity
- **(World first)** Demonstrating the effects of the tumor lysis viral preparation "Telomelysin"

